Exelixis(EXEL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of$437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of$0.84 - - U.S. Food and Drug Administration (FDA) Acc ...